A Smooth Blood Pressure Control is obtained over 24 h by Delapril in Mild to Moderate Essential Hypertensives

Objective: To assess the homogeneity of the antihypertensive effect of delapril over 24 h. Design and methods: After 2 weeks of placebo 50 mild to moderate essential hypertensives (age 54 - 5 years) were subjected to 8 weeks of treatment with delapril 30 mg once daily. At the end of each period, blood pressure (BP) was assessed by conventional sphygmomanometry (clinic or CBP) and ambulatory (A) BP monitoring. Twenty-four-hour means, trough-to-peak ratio (T/P) and smoothness index (SI, the ratio between the average of the 24-h BP changes after T and its standard deviation) were calculated for systolic (S) and diastolic (D) BP. Results: CBP and ABP were significantly reduced by treatment. Pulse pressure (PP, the SBP-DBP difference) was also significantly ( p < 0.01) reduced by delapril (5.7 - 6.2 and 3.3 - 3.8 mmHg, CPP and APP). The median T/P was higher (0.51 and 0.62, SBP and DBP) in the 43 responders at trough than in the whole group (0.44 and 0.51). The SI was similarly high in the whole group (1.3 - 0.6 and 1.4 - 0.6, SBP and DBP) and in the responders (1.4 - 0.5 and 1.5 - 0.6). Conclusions: Delapril effectively and smoothly reduces BP over 24 h, this effect being evident also on PP, a parameter with a relevant prognostic value.

[1]  N. Kaplan Guidelines for the management of hypertension. , 2000, The Canadian journal of cardiology.

[2]  Toshio Ogihara Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan. , 2000, American journal of hypertension.

[3]  V. Burke,et al.  Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial. , 1999, Journal of hypertension.

[4]  F. Zannad,et al.  Ambulatory 24-h blood pressure assessment of the felodipine-metoprolol combination versus amlodipine in mild to moderate hypertension. Lorraine General Physician Investigators Group. , 1999, Journal of hypertension.

[5]  G. Parati,et al.  The smoothness index: A new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension , 1998, Journal of hypertension.

[6]  M. Safar,et al.  Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. , 1998, Hypertension.

[7]  Giuseppe Mancia,et al.  Risk factors associated with alterations in carotid intima—media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis , 1998, Journal of hypertension.

[8]  G. Parati,et al.  The trough:peak ratio and the smoothness index in the evaluation of control of 24 h blood pressure by treatment in hypertension. , 1998, Blood pressure monitoring.

[9]  S. Julius,et al.  Heart rate and the cardiovascular risk , 1997, Journal of hypertension.

[10]  J. Webster,et al.  Ambulatory monitoring uncorrected for placebo overestimates long-term antihypertensive action. Systolic Hypertension in Europe (SYST-EUR) Trial Investigators. , 1996, Hypertension.

[11]  G. Parati,et al.  Calculation of trough: peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects , 1995, Journal of hypertension.

[12]  G. Parati,et al.  Lack of placebo effect on ambulatory blood pressure. , 1995, American journal of hypertension.

[13]  Lipicky Rj,et al.  Trough: peak ratio the rationale behind the United States Food and Drug Administration recommendations , 1994, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[14]  G Mancia,et al.  Prognostic value of 24-hour blood pressure variability , 1993, Journal of hypertension.

[15]  P. Hjemdahl,et al.  Converting enzyme inhibition modulates sympathetic neurotransmission in vivo via multiple mechanisms. , 1993, The American journal of physiology.

[16]  K. Arakawa,et al.  Effects of manidipine and delapril on serum lipids, lipoproteins, and apolipoproteins in patients with mild to moderate essential hypertension: a randomized trial with one-year follow-up. , 1992, Clinical Therapeutics.

[17]  P. Palatini,et al.  Clinical relevance of nighttime blood pressure and of daytime blood pressure variability. , 1992, Archives of internal medicine.

[18]  A. Dupont,et al.  Placebo does not lower ambulatory blood pressure. , 1987, British journal of clinical pharmacology.

[19]  R S Paffenbarger,et al.  Heart rate and cardiovascular mortality: the Framingham Study. , 1987, American heart journal.

[20]  G Parati,et al.  Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. , 1987, Journal of hypertension.

[21]  J. Ferlinz DOES PLACEBO LOWER BLOOD PRESSURE? , 1982, The Lancet.

[22]  F. Zannad,et al.  Double-blind, randomized, multicentre comparison of the effects of amlodipine and perindopril on 24 h therapeutic coverage and beyond in patients with mild to moderate hypertension , 1999 .

[23]  R. Dietz,et al.  Improvement of vagal tone by ACE inhibition: a mechanism of cardioprotection in patients with mild-to-moderate heart failure. , 1996, Journal of cardiovascular pharmacology.

[24]  H. Matsuoka A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension--The GLANT Study. Study Group on Long-term Antihypertensive Therapy. , 1995, Hypertension research : official journal of the Japanese Society of Hypertension.

[25]  T. Ogihara,et al.  Effect of long-term treatment with delapril on quality of life in hypertensive patients , 1992 .

[26]  Y. Yamada,et al.  A study of the effects of delapril, a new angiotensin converting enzyme inhibitor, on the diurnal variation of arterial pressure in patients with essential hypertension using indirect and direct arterial pressure monitoring methods. , 1991, American journal of hypertension.

[27]  T. Saruta,et al.  Characteristics of a new angiotensin converting enzyme inhibitor: delapril. , 1991, American journal of hypertension.

[28]  T. Ogihara,et al.  Clinical evaluation of delapril in Japan. Report from the Japan Study Group on Delapril. , 1991, American journal of hypertension.